Upcoming Events
Life Science Investor Reception 2026
Life Science Investor Reception 2026
Elevate Your BIO Week Experience at an Exclusive Investor Networking Reception!
Make the most of your BIO Week with an exceptional networking opportunity designed to connect healthcare and life sciences investors with leading biotech and life sciences entrepreneurs.
Why Attend?
Meet dozens of top-tier investors and influential industry leaders in an intimate, high-value setting.
Connect with innovative companies driving breakthroughs in healthcare and biotech.
Expand your network with like-minded professionals, entrepreneurs, and decision-makers.
Hosted annually by CONNECTpreneur and Opus8., this event offers an exclusive chance to build relationships that can shape the future of healthcare and life sciences.
Event Details
Monday, June 22, 2026
5 - 7 pm PDT
Fogo de Chão Brazilian Steakhouse
668 Sixth Ave, San Diego, CA 92101
Enjoy light fare and unlimited premium beverages in a relaxed, upscale atmosphere.
Who Should Attend?
VCs and Accredited investors passionate about healthcare, biotech, and life sciences.
Entrepreneurs and founders seeking capital and partnerships.
Attendance will be Limited!
This event is highly sought after, with limited spots available to ensure meaningful connections. Reserve your seat today before space runs out!
Take the First Step
Discover the partnerships and insights that could define your 2026.
Register Now to secure your spot and begin your BIO Week on the right note!
Sponsorship and Exhibitor Opportunities
Elevate your brand in front of a highly curated audience of investors and industry leaders. For more information, please contact Avery North at anorth@opus8.com.
IGC Pharma Private Investor Briefing - Virtual
IGC Pharma Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
Thursday, June 25, 11:30 am EDT
Dear Investors,
Opus8 and the New York Private Equity Forum (NYPEF) are hosting a private investor briefing with IGC Pharma (NYSE American: IGC), a clinical-stage biotechnology and AI company developing novel therapeutics and predictive intelligence platforms focused on Alzheimer’s disease.
Company Overview
IGC Pharma is a clinical-stage biotechnology and AI company focused on developing innovative solutions for Alzheimer’s disease. The company’s lead therapeutic candidate, IGC-AD1, is currently advancing through a Phase 2 clinical trial targeting agitation in Alzheimer’s disease (AAD), a significant unmet need affecting millions of patients worldwide.
With several anticipated clinical and operational milestones expected in the coming months, IGC Pharma is positioned at the intersection of biotechnology, artificial intelligence, and one of healthcare’s largest and fastest-growing markets.
Key Highlights
• Phase 2 clinical trial nearing completion with multiple anticipated catalysts over the next 4–9 months
• Addressing a significant unmet need in Alzheimer’s disease, a market affecting more than 40 million people globally
• Lead therapeutic candidate designed to improve upon limitations of current treatment options
• AI-powered healthcare platform creating additional growth opportunities beyond therapeutics
• Positioned at the intersection of biotechnology, artificial intelligence, and aging-related healthcare innovation
• Publicly traded with a current valuation significantly below comparable Alzheimer's-focused biotech companies
Event Details:
Date: June 25
Time: 11:30 am - 12:30 pm
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
Master Class: The AI Workforce Playbook for GTM Teams
The AI Workforce Playbook for GTM Teams
Thursday, June 25, 2026, 1 pm ET
What if every member of your GTM team had an AI teammate?
In this master class, you'll learn how to use Claude to automate account research, prioritize target accounts, generate personalized outreach at scale, and create AI-powered workflows that expand your team's execution capacity.
Michael Yee of Tiga AI will walk through practical examples showing how modern GTM leaders are building AI workforces to drive more pipeline, eliminate repetitive work, and execute faster without adding headcount.
Seats are limited, register today!
About your Instructor:
Michael Yee is co-founder and head of product engineering for Tiga AI - a leading provider of AI agents for sales and marketing. He has extensive experience in the development of autonomous agents and has spoken at various events on the topic of AI agents applied to B2B enterprises. Prior to Tiga, Michael was the Lead Software Engineer at Triblio, overseeing high-performing teams and delivering projects on time. He has written articles on AI, web3, and other emerging technologies. In his free time, Michael indulges in drumming and running.
HomeRoots Private Investor Briefing - CA
HomeRoots Private Investor Briefing - CA
by CONNECTpreneur Investor Network
Monday, June 29, 5:30 pm PDT
Dear Investors,
Opus8 is hosting a private investor reception featuring HomeRoots, an AI-powered B2B marketplace modernizing wholesale distribution in the $400B home products industry.
HomeRoots is solving one of the largest inefficiencies in retail commerce — enabling manufacturers to seamlessly access major retailers, e-commerce platforms, hospitality groups, and commercial buyers through a proprietary AI-driven platform.
The platform dramatically reduces onboarding costs and time-to-market while improving product accuracy, advertising performance, and operational scalability for suppliers and retailers alike.
Why investors are taking notice:
AI-powered infrastructure for wholesale commerce
Serving a $400B global home products market
$5M FY2025 revenue with 50% YoY growth in 2026
600+ manufacturers in network with expanding retailer partnerships
Strong operating leverage with scalable, asset-light model
Leadership team with deep retail, eCommerce, and marketplace expertise
Positioned to benefit from major shifts in global supply chain and retail distribution
HomeRoots is building the next-generation operating system for B2B commerce — combining marketplace distribution, automation, and AI to modernize how products move from manufacturers to retailers at scale.
Join us for an exclusive evening to meet the leadership team, hear the company's growth strategy firsthand, and explore the investment opportunity.
Event Details:
Date: June 29
Time: 5:30 pm - 6:30 pm
Location: Bay Area, CA
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
CONNECTpreneur INVESTOR Network: Virtual Meeting
CONNECTpreneur INVESTOR Network: Virtual Meeting
Thursday, August 5, 2026, 11am ET
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
We will email you the Zoom link on the evening of October 28th, as well as the morning of October 29th.
About this Meeting:
CONNECTpreneur prides itself on having the largest community of accredited investors, VCs, private investors, and angels.
This 1 hour CONNECTpreneur INVESTOR Network Virtual Meeting is an exclusive, investors-only virtual meeting featuring curated 4-minute pitches from top early-stage ventures. This closed-door session brings together accredited investors, VCs, angels, and private capital to discover new opportunities. Join us for a focused, private Zoom meeting that streamlines deal flow and encourages active investment discussions.
Program Highlights:
Exclusive Investor-Only Access– A private, closed-door gathering for accredited investors, VCs, angels, and family offices. The only attendees at this meeting will be the presenters and investors.
Curated Company Presentations – Handpicked, early-stage ventures showcase their opportunities to an investor-only audience.
High-Value Deal Flow – Direct access to innovative startups and ventures seeking capital.
Direct Investor Networking– Connect and build relationships with other investors in a trusted environment.
Focused Format – No distractions. Just quality presentations and meaningful investor interactions.
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
CONNECTpreneur INVESTOR Network: Virtual Meeting
CONNECTpreneur INVESTOR Network: Virtual Meeting
Thursday, October 29, 2026, 11am ET
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
We will email you the Zoom link on the evening of October 28th, as well as the morning of October 29th.
About this Meeting:
CONNECTpreneur prides itself on having the largest community of accredited investors, VCs, private investors, and angels.
This 1 hour CONNECTpreneur INVESTOR Network Virtual Meeting is an exclusive, investors-only virtual meeting featuring curated 4-minute pitches from top early-stage ventures. This closed-door session brings together accredited investors, VCs, angels, and private capital to discover new opportunities. Join us for a focused, private Zoom meeting that streamlines deal flow and encourages active investment discussions.
Program Highlights:
Exclusive Investor-Only Access– A private, closed-door gathering for accredited investors, VCs, angels, and family offices. The only attendees at this meeting will be the presenters and investors.
Curated Company Presentations – Handpicked, early-stage ventures showcase their opportunities to an investor-only audience.
High-Value Deal Flow – Direct access to innovative startups and ventures seeking capital.
Direct Investor Networking– Connect and build relationships with other investors in a trusted environment.
Focused Format – No distractions. Just quality presentations and meaningful investor interactions.
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
HomeRoots Private Investor Briefing - Tysons Corner, VA
HomeRoots Private Investor Briefing - Tysons Corner, VA
by CONNECTpreneur Investor Network
Monday, June 18, 5:30 pm EDT
Dear Investors,
Opus8 is hosting a private investor reception featuring HomeRoots, an AI-powered B2B marketplace modernizing wholesale distribution in the $400B home products industry.
HomeRoots is solving one of the largest inefficiencies in retail commerce — enabling manufacturers to seamlessly access major retailers, e-commerce platforms, hospitality groups, and commercial buyers through a proprietary AI-driven platform.
The platform dramatically reduces onboarding costs and time-to-market while improving product accuracy, advertising performance, and operational scalability for suppliers and retailers alike.
Why investors are taking notice:
AI-powered infrastructure for wholesale commerce
Serving a $400B global home products market
$5M FY2025 revenue with 50% YoY growth in 2026
600+ manufacturers in network with expanding retailer partnerships
Strong operating leverage with scalable, asset-light model
Leadership team with deep retail, eCommerce, and marketplace expertise
Positioned to benefit from major shifts in global supply chain and retail distribution
HomeRoots is building the next-generation operating system for B2B commerce — combining marketplace distribution, automation, and AI to modernize how products move from manufacturers to retailers at scale.
Join us for an exclusive evening to meet the leadership team, hear the company's growth strategy firsthand, and explore the investment opportunity.
Event Details:
Date: June 18
Time: 5:30 pm - 6:30 pm
Location: Tysons Corner, VA
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
Traderware Private Investor Briefing - Virtual
Traderware Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
Tuesday, June 16, 5:30 pm EDT
Dear Investors,
Opus8 and the New York Private Equity Forum (NYPEF) are hosting a private investor briefing with Traderware, the company behind Traderverse — an infrastructure platform for social engagement and intelligence in capital markets.
Traderware enables financial institutions to integrate identity, community, and AI-powered engagement directly into regulated investment environments.
Company Overview
Traderware is building Traderverse, an infrastructure layer that enables financial institutions to integrate identity, community, and AI-driven engagement directly into their investment environments.
The platform brings investor interaction and intelligence into first-party institutional systems, replacing fragmented external channels with a compliant, integrated engagement layer.
Key Highlights
• Verified Identity Infrastructure for Markets — Enables trusted identity and reputation layers for compliant investor engagement
• Institutional Integration Layer — API-driven infrastructure designed for brokerages, exchanges, and financial platforms
• AI-Powered Engagement Tools — Embeds intelligence and personalization directly into investor workflows
• Compliance-Ready Social Framework — Supports community, discussion, and gamification within regulated environments
• Multi-Channel Distribution Footprint — Reaches 300,000+ news bot subscribers, 75,000+ social followers, and 25,000+ newsletter subscribers
• Institutional-Grade Team & Advisory Network — Supported by a 40-person product, engineering, and finance team with advisors from NYSE, Goldman Sachs, Intuit, Adobe, and Nike Digital
Event Details:
Date: June 16
Time: 11:30 am - 12:30 pm
Location: Online via Zoom
For more information about Traderware, visit their website: https://traderware.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
HomeRoots Private Investor Briefing - NYC
HomeRoots Private Investor Briefing - NYC
by CONNECTpreneur Investor Network
Monday, June 15, 5:30 pm EDT
Dear Investors,
Opus8 and the New York Private Equity Forum (NYPEF) are hosting a private investor reception featuring HomeRoots, an AI-powered B2B marketplace modernizing wholesale distribution in the $400B home products industry.
HomeRoots is solving one of the largest inefficiencies in retail commerce — enabling manufacturers to seamlessly access major retailers, e-commerce platforms, hospitality groups, and commercial buyers through a proprietary AI-driven platform.
The platform dramatically reduces onboarding costs and time-to-market while improving product accuracy, advertising performance, and operational scalability for suppliers and retailers alike.
Why investors are taking notice:
AI-powered infrastructure for wholesale commerce
Serving a $400B global home products market
$5M FY2025 revenue with 50% YoY growth in 2026
600+ manufacturers in network with expanding retailer partnerships
Strong operating leverage with scalable, asset-light model
Leadership team with deep retail, eCommerce, and marketplace expertise
Positioned to benefit from major shifts in global supply chain and retail distribution
HomeRoots is building the next-generation operating system for B2B commerce — combining marketplace distribution, automation, and AI to modernize how products move from manufacturers to retailers at scale.
Join us for an exclusive evening to meet the leadership team, hear the company's growth strategy firsthand, and explore the investment opportunity.
Event Details:
Date: June 15
Time: 5:30 pm - 6:30 pm
Location: New York, NY
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
Traderware Private Investor Briefing - NYC
Traderware Private Investor Briefing - NYC
by CONNECTpreneur Investor Network
THURSDAY, June 11, 5:30 pm EDT
Dear Investors,
Opus8 and the New York Private Equity Forum (NYPEF) are hosting a private investor briefing with Traderware, the company behind Traderverse — an infrastructure platform for social engagement and intelligence in capital markets.
Traderware enables financial institutions to integrate identity, community, and AI-powered engagement directly into regulated investment environments.
Company Overview
Traderware is building Traderverse, an infrastructure layer that enables financial institutions to integrate identity, community, and AI-driven engagement directly into their investment environments.
The platform brings investor interaction and intelligence into first-party institutional systems, replacing fragmented external channels with a compliant, integrated engagement layer.
Key Highlights
• Verified Identity Infrastructure for Markets — Enables trusted identity and reputation layers for compliant investor engagement
• Institutional Integration Layer — API-driven infrastructure designed for brokerages, exchanges, and financial platforms
• AI-Powered Engagement Tools — Embeds intelligence and personalization directly into investor workflows
• Compliance-Ready Social Framework — Supports community, discussion, and gamification within regulated environments
• Multi-Channel Distribution Footprint — Reaches 300,000+ news bot subscribers, 75,000+ social followers, and 25,000+ newsletter subscribers
• Institutional-Grade Team & Advisory Network — Supported by a 40-person product, engineering, and finance team with advisors from NYSE, Goldman Sachs, Intuit, Adobe, and Nike Digital
Event Details:
Date: June 11
Time: 5:30 pm - 7:30 pm
Location: NYC
For more information about Traderware, visit their website: https://traderware.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
C2RE Private Investor Briefing - Virtual
C2RE Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
THURSDAY, June 11, 11:30 am EDT
Dear Investors,
Opus8 is hosting a private investor briefing with C2RE.
C2RE is fundamentally disrupting the rare earths landscape by introducing a highly scalable platform for next-gen defense tech infrastructure. We are eliminating geopolitical supply chain vulnerabilities through proprietary nanocarbon solutions that replace or optimize critical rare earths.
C2RE's technology is lower-cost and more eco-friendly vs. traditional rare earth mining through a proprietary myco-mining process and modular “factory on wheels” infrastructure designed for rapid deployment.
The briefing will include an overview of the company’s technology, commercialization strategy, licensing model, industry partnerships, and plans to scale pilot operations across multiple resource sites.
Join an exclusive group of deep tech investors for a private briefing on how we are scaling this disruptive, dual-use technology for global market dominance.
Key highlights include:
Proprietary scalable bio-leaching platform
Critical minerals markets: defense, AI infrastructure, semiconductors, and energy technologies
Traction: Partnership and university engagement across domestic and international mining organizations
Licensing and royalty-based revenue model with infrastructure-lite deployment
Focus on rare earth extraction from existing waste materials rather than new mining
Event Details:
Date: June 11
Time: 11:30 am - 12:30 pm
Location: Online via Zoom
For more information about C2RE, visit their website: https://nanocarbonsolutions.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
C2RE Private Investor Briefing - Tysons Corner
C2RE Private Investor Briefing - Tysons Corner
by CONNECTpreneur Investor Network
TUESDAY, June 9, 5:30 pm EDT
Dear Investors,
Opus8 is hosting a private investor briefing with C2RE.
C2RE is fundamentally disrupting the rare earths landscape by introducing a highly scalable platform for next-gen defense tech infrastructure. We are eliminating geopolitical supply chain vulnerabilities through proprietary nanocarbon solutions that replace or optimize critical rare earths.
C2RE's technology is lower-cost and more eco-friendly vs. traditional rare earth mining through a proprietary myco-mining process and modular “factory on wheels” infrastructure designed for rapid deployment.
The briefing will include an overview of the company’s technology, commercialization strategy, licensing model, industry partnerships, and plans to scale pilot operations across multiple resource sites.
Join an exclusive group of deep tech investors for a private briefing on how we are scaling this disruptive, dual-use technology for global market dominance.
Key highlights include:
Proprietary scalable bio-leaching platform
Critical minerals markets: defense, AI infrastructure, semiconductors, and energy technologies
Traction: Partnership and university engagement across domestic and international mining organizations
Licensing and royalty-based revenue model with infrastructure-lite deployment
Focus on rare earth extraction from existing waste materials rather than new mining
Event Details:
Date: June 9
Time: 5:30 pm - 7:30 pm
Location: Tysons Plaza, 1420 Spring Hill Rd, McLean, VA 22102
1st Floor Conference Center
Enter through the lobby, the conference center is on the left
For more information about C2RE, visit their website: https://nanocarbonsolutions.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
Big Idea CONNECTpreneur Forum - JUNE 4, IN PERSON McLEAN, VA
CONNECTpreneur Forums are bi-monthly in person networking mashups, which have been attended by over 45,000 business leaders over the past 15 years.
Space is very limited at this venue, and this will another Sold Out in person event, so there will be no on-site registration.
All attendees must be pre-registered.
Program Highlights:
- We are capping attendance at 180+ business leaders, including 75+ angels and private investors, family offices, etc.
-Investor Spotlight featuring leading early stage VCs in the DMV region
- Showcase of Emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.
- Heavy networking before, during, and after the event
Beverages and light fare will be provided.
Special Guests and Speakers:
TIEN WONG, Founder and Host, CONNECTpreneur; CEO, Opus8, Inc.
RAE STOTT, CEO, Refraction
JOHN NEWBY, CEO, Virginia Bio
ANNA NISSINEN, Senior Vice President, Fairfax County Economic Development Authority
JENNIFER TAYLOR , CEO, The Northern Virginia Technology Council (NVTC)
Investor Spotlight:
MAURICE BOISSIERE, Partner & Chief Customer Officer, DataTribe
DEBORAH HEMINGWAY, Managing Partner, Ecphora Capital
TOM WEITHMAN, Managing Director, Virginia Venture Partners
INVITED: Blu Venture Investors
Companies will be introduced by:
ANTHONY MILLIN, NEXT Chair, Partner, Shulman Rogers
DEBBIE CLINE, Founder and Chief of Customer Success, Buzzy Rocket
Traderware Private Investor Briefing - Tysons Corner
Traderware Private Investor Briefing - Tysons Corner
by CONNECTpreneur Investor Network
TUESDAY, June 2, 5:30 pm EDT
Dear Investors,
Opus8 and the New York Private Equity Forum (NYPEF) are hosting a private investor briefing with Traderware, the company behind Traderverse — an infrastructure platform for social engagement and intelligence in capital markets.
Traderware enables financial institutions to integrate identity, community, and AI-powered engagement directly into regulated investment environments.
Company Overview
Traderware is building Traderverse, an infrastructure layer that enables financial institutions to integrate identity, community, and AI-driven engagement directly into their investment environments.
The platform brings investor interaction and intelligence into first-party institutional systems, replacing fragmented external channels with a compliant, integrated engagement layer.
Key Highlights
• Verified Identity Infrastructure for Markets — Enables trusted identity and reputation layers for compliant investor engagement
• Institutional Integration Layer — API-driven infrastructure designed for brokerages, exchanges, and financial platforms
• AI-Powered Engagement Tools — Embeds intelligence and personalization directly into investor workflows
• Compliance-Ready Social Framework — Supports community, discussion, and gamification within regulated environments
• Multi-Channel Distribution Footprint — Reaches 300,000+ news bot subscribers, 75,000+ social followers, and 25,000+ newsletter subscribers
• Institutional-Grade Team & Advisory Network — Supported by a 40-person product, engineering, and finance team with advisors from NYSE, Goldman Sachs, Intuit, Adobe, and Nike Digital
Event Details:
Date: June 2
Time: 5:30 pm - 7:30 pm
Location: Exact location will be provided upon approval
For more information about Traderware, visit their website: https://traderware.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
CONNECTpreneur INVESTOR Network: Virtual Meeting
CONNECTpreneur INVESTOR Network: Virtual Meeting
Thursday, May 28, 2026, 11am ET
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
We will email you the Zoom link on the evening of May 27th, as well as the morning of May 28th.
About this Meeting:
CONNECTpreneur prides itself on having the largest community of accredited investors, VCs, private investors, and angels.
This 1 hour CONNECTpreneur INVESTOR Network Virtual Meeting is an exclusive, investors-only virtual meeting featuring curated 4-minute pitches from top early-stage ventures. This closed-door session brings together accredited investors, VCs, angels, and private capital to discover new opportunities. Join us for a focused, private Zoom meeting that streamlines deal flow and encourages active investment discussions.
Program Highlights:
Exclusive Investor-Only Access– A private, closed-door gathering for accredited investors, VCs, angels, and family offices. The only attendees at this meeting will be the presenters and investors.
Curated Company Presentations – Handpicked, early-stage ventures showcase their opportunities to an investor-only audience.
High-Value Deal Flow – Direct access to innovative startups and ventures seeking capital.
Direct Investor Networking– Connect and build relationships with other investors in a trusted environment.
Focused Format – No distractions. Just quality presentations and meaningful investor interactions.
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
ColdSnap Private Investor Briefing - Virtual
ColdSnap Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
FRIDAY, May 1, 11:30 am EDT
Dear Investors,
Opus8 and New York Private Equity Forums (NYPEF) are hosting an in-person, invitation-only private investor briefing featuring ColdSnap, a company redefining how frozen treats are produced and served through its proprietary rapid-freezing technology.
Company Overview
ColdSnap has developed a commercial-grade countertop appliance that instantly creates premium frozen treats: ice cream, frozen coffee, smoothies, and protein shakes—from shelf-stable pods. By eliminating the need for refrigeration, storage, and traditional supply chains, the company enables on-demand, single-serve production with minimal waste. Positioned at the intersection of food tech and convenience, ColdSnap targets high-traffic commercial environments with a scalable, asset-light model.
What Differentiates ColdSnap
• Instant, On-Demand Production — Delivers frozen products in under two minutes with no prep or cleanup
• No Cold Chain Required — Shelf-stable pods remove the need for freezing, storage, and spoilage concerns
• Versatile Platform — Supports a wide range of products including ice cream, frozen beverages, and nutritional shakes
• Commercial Scalability — Designed for offices, hospitality, healthcare, and foodservice environments
• Recurring Revenue Model — Razor-and-blade model driven by high-margin consumable pods
• Proven Leadership — Led by a team with deep experience in consumer appliances and food innovation
Event Details:
Date: May 1
Time: 11:30 am
Location: Online via Zoom
For more information about ColdSnap, visit their website: https://coldsnap.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
InventWood Confidential Investor Update - Virtual
InventWood Confidential Investor Update - Virtual
by CONNECTpreneur Investor Network
WEDNESDAY, April 29, 12:00 pm EDT
Dear Investors:
Opus8 and NYPEF are hosting a small, invitation-only confidential investor update call featuring InventWood, a materials company commercializing SUPERWOOD™, a biomaterial delivering the strength of steel with the aesthetics of wood.
This closed-door session provides direct access to leadership and a focused discussion of the company’s proprietary platform, early commercial traction, manufacturing scale-up, and current financing opportunities for accredited investors.
InventWood is entering a key value-creation phase with automated manufacturing live, shipments underway, and accelerating demand as steel and concrete face rising costs and constraints.
Company Overview
InventWood has commercialized SUPERWOOD™, a structural biomaterial that is stronger than steel, significantly lighter, fire resistant, and carbon sequestering. Its proprietary process transforms wood by eliminating defects and increasing intrinsic strength and durability.
The company is entering through premium building applications and expanding toward large structural and infrastructure markets.
What Differentiates InventWood
• Category-Defining Material — Steel-level strength at a fraction of the weight
• Proprietary Platform — Molecular re-engineering of wood
• Commercialization Underway — Manufacturing live, shipments in market
• Defensible IP — 140+ patents
• Capital-Efficient Scale-Up — Premium markets fund expansion
• Large Market Pull — $750B+ addressable markets
Event Details
Date: Wednesday, April 29, 2026
Time: 12 pm EDT
Location: Online via Zoom
Attendance is strictly limited and curated.
Important Notes
This meeting is for DIRECT, ACTIVE and ACCREDITED private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.
Attendees must sign an NDA before the meeting.
To request investor materials in advance, please contact:
Avery North — anorth@opus8.com
Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
ColdSnap Private Investor Briefing - NYC
ColdSnap Private Investor Briefing - NYC
by CONNECTpreneur Investor Network
THURSDAY, March 5, 1:00 pm EST
Dear Investors,
Opus8 and New York Private Equity Forums (NYPEF) are hosting an in-person, invitation-only private investor briefing featuring ColdSnap, a company redefining how frozen treats are produced and served through its proprietary rapid-freezing technology.
Company Overview
ColdSnap has developed a commercial-grade countertop appliance that instantly creates premium frozen treats: ice cream, frozen coffee, smoothies, and protein shakes—from shelf-stable pods. By eliminating the need for refrigeration, storage, and traditional supply chains, the company enables on-demand, single-serve production with minimal waste. Positioned at the intersection of food tech and convenience, ColdSnap targets high-traffic commercial environments with a scalable, asset-light model.
What Differentiates ColdSnap
• Instant, On-Demand Production — Delivers frozen products in under two minutes with no prep or cleanup
• No Cold Chain Required — Shelf-stable pods remove the need for freezing, storage, and spoilage concerns
• Versatile Platform — Supports a wide range of products including ice cream, frozen beverages, and nutritional shakes
• Commercial Scalability — Designed for offices, hospitality, healthcare, and foodservice environments
• Recurring Revenue Model — Razor-and-blade model driven by high-margin consumable pods
• Proven Leadership — Led by a team with deep experience in consumer appliances and food innovation
Event Details:
Date: April 23
Time: 5:30 pm
Location: Bad Roman
10 Columbus Circle, Third Floor
New York, NY
For more information about ColdSnap, visit their website: https://coldsnap.com/
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
ARC Medical Private Investor Briefing - Virtual
ARC Medical Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
TUESDAY, April 21, 11:30 am EDT
Dear Investors:
Please join us for an invitation only virtual private investor meeting on Zoom, featuring ARC Medical, on Tuesday, April 21, 2026.
This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).
ARC is one of the most exciting life sciences companies we have seen! ARC significantly improves surgical patient recovery by preventing internal adhesions, the most common complication in knee, shoulder, gynecological and abdominal surgeries.
Key Investment Considerations
Massive Markets: 11 million patients yearly and a TAM $11 billion
Excellent Efficacy and Clinical Data: for company’s lead products for knee and shoulder surgeries
Strong IP Provide Exclusivity: multiple patents granted that provide exclusivity for the company’s products through 2039 and beyond.
Great Fundrasing traction: ARC has already raised $39 million ($21M in equity and $18M in non-dilutive revenue and grants), and will close the current round in a matter of weeks.
Unicorn-level Exit Potential: representing a 20X return based on comparable companies in the wound healing arena.
World Class Team: has designed, developed multi $billion products for companies including J&J, Stryker, Smith+Nephew, Amgen and Moderna
Event Details:
Date: April 21
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
Big Idea CONNECTpreneur Forum - April 16, IN PERSON in DC
CONNECTpreneur Forums are bi-monthly in person networking mashups, which have been attended by over 35,000 business leaders over the past 14 years.
Space is very limited at this venue, and this will another Sold Out in person event, so there will be no on-site registration.
All attendees must be pre-registered.
Program Highlights:
- We are capping attendance at 180+ business leaders, including 75+ angels and private investors, family offices, etc.
- Showcase of Emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.
- Heavy networking before, during, and after the event
Beverages and light fare will be provided.
i-Lumen Scientific Private Investor Briefing - Virtual
i-Lumen Scientific Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
TUESDAY, April 14, 11:30 am EDT
Dear Investors,
Opus8 is hosting a virtual, invitation-only private investor briefing featuring i-Lumen Scientific, an ophthalmology company developing a non-invasive treatment designed to restore vision in patients with Dry Age-Related Macular Degeneration (Dry-AMD).
This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).
Company Overview
i-Lumen is advancing a non-invasive, physician-delivered therapy designed to restore vision in Dry-AMD patients, with clinical data demonstrating meaningful improvement. Operating in a large, underserved market, the company is positioned for near-term value inflection through its pivotal trial and planned FDA pathway.
What Differentiates i-Lumen
• Demonstrated Clinical Results — Patients showed meaningful vision improvement with sustained outcomes
• Non-Invasive Approach — Physician-delivered therapy designed to restore, not just preserve, vision
• Large Market Opportunity — 200M+ patients globally, with significant unmet need
• Strategic Positioning — Strong acquisition precedent in ophthalmology, including recent $850M transaction
• Active Raise — Currently raising a $35M Series B, with $18M already committed
Event Details:
Date: Tuesday, April 14
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
NeuroEM Private Investor Briefing - Virtual
NeuroEM Therapeutics Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
THURSDAY, April 2, 11:30 am EDT
Dear Investors,
Opus8 is hosting a virtual, invitation-only private investor briefing featuring NeuroEM, a medical technology company developing a non-invasive treatment designed to slow and potentially reverse the effects of Alzheimer’s disease.
NeuroEM’s patented TEMT-RF (Transcranial Electro-Magnetic Treatment using Radio Frequencies) platform targets the underlying biological drivers of Alzheimer’s by reducing toxic protein buildup, decreasing inflammation, and restoring cellular energy in the brain. The company’s device has received FDA Breakthrough Device designation, positioning it at the forefront of next-generation neurological therapeutics.
Company Overview
NeuroEM is advancing a clinically validated, non-pharmaceutical treatment approach for Alzheimer’s disease—one of the largest and fastest-growing healthcare challenges globally. Built on more than a decade of university research and supported by NIH funding, NeuroEM’s technology has demonstrated measurable cognitive improvement in early clinical trials and is designed to deliver scalable, at-home treatment for millions of patients.
What Differentiates NeuroEM
• Breakthrough Clinical Results — In early clinical trials, 7 of 8 Alzheimer’s patients showed measurable cognitive improvement within two months of treatment
• Strong Scientific Foundation — 10+ years of university research, supported by two NIH grants and extensive peer-reviewed validation
• Robust Intellectual Property — 9 issued patents with 10 additional patents pending worldwide
• Massive Market Opportunity — Alzheimer’s affects 55M+ patients globally, representing a healthcare market exceeding $300B annually
• Capital Efficient Growth — Currently raising a $5M Seed Preferred round at a $15M pre-money valuation, with a planned $5–10M Series A
Event Details:
Date: Thursday, April 2
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO,
Opus8, Inc.
ARC Medical Private Investor Briefing - Virtual
ARC Medical Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
THURSDAY, March 5, 1:00 pm EST
Please join us for an invitation only virtual private investor meeting on Zoom, featuring ARC Medical, on Tuesday, March 3`1st, 2026.
ARC is one of the most exciting life sciences companies we have seen! ARC significantly improves surgical patient recovery by preventing internal adhesions, the most common complication in knee, shoulder, gynecological and abdominal surgeries.
Key Investment Considerations
Massive Markets: 11 million patients yearly and a TAM $11 billion
Excellent Efficacy and Clinical Data: for company’s lead products for knee and shoulder surgeries
Strong IP Provide Exclusivity: multiple patents granted that provide exclusivity for the company’s products through 2039 and beyond.
Great Fundrasing traction: ARC has already raised $39 million ($21M in equity and $18M in non-dilutive revenue and grants), and will close the current round in a matter of weeks.
Unicorn-level Exit Potential: representing a 20X return based on comparable companies in the wound healing arena.
World Class Team: has designed, developed multi $billion products for companies including J&J, Stryker, Smith+Nephew, Amgen and Moderna
Event Details:
Date: March 31
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO,
Opus8, Inc.
Intrommune Private Investor Briefing - Virtual
Intrommune Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
MONDAY, March 23, 11:30 am EDT
Dear Investors,
Opus8 is hosting a virtual, invitation-only private investor briefing featuring Intrommune, a consumer health company pioneering a new approach to peanut allergy prevention.
Intrommune’s patented platform delivers allergens through a familiar daily routine—brushing your teeth. By administering controlled exposure through toothpaste, the technology trains the immune system and aims to prevent life-threatening peanut allergies through a simple, consumer-friendly delivery method.
Company Overview
Intrommune is developing a consumer-grade immunotherapy platform designed to make allergy prevention safe, simple, and scalable. By combining biotech-grade science with a routine daily behavior, the company is creating a new category in preventive allergy care. With early clinical validation and commercial traction already underway, Intrommune is positioned at the intersection of healthcare innovation and consumer accessibility.
What Differentiates Intrommune
• Clinically Validated Approach — In the Phase 1 peanut allergy study, patients achieved 97% adherence with zero dropouts and zero cases of anaphylaxis
• Early Commercial Traction — The company began generating revenue through its distribution channels in November 2025
• Large and Underserved Market — More than 33 million Americans suffer from food allergies, with limited treatment options currently available
• First-Mover Consumer Platform — The only biotech-grade allergy immunotherapy delivered in a consumer-ready toothpaste format
• Experienced Leadership — Led by seasoned executives and advisors from across biotech, healthcare, and consumer health
Event Details:
Date: March 23
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO,
Opus8, Inc.
Saltenna Private Investor Briefing - Virtual
Saltenna Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
TUESDAY, March 17, 11:30 am EDT
Dear Investors:
Opus8 is hosting a virtual, invitation-only private investor briefing featuring Saltenna, a wireless communications company enabling high-bandwidth connectivity in oceans, ice, dense terrain, underground environments, and metal infrastructure—areas where traditional RF systems fail.
Using proprietary Surface Electromagnetic Wave technology, Saltenna transmits signals without line of sight, unlocking secure communications across the 80%+ of the Earth previously considered unreachable.
Company Overview
Saltenna has developed a patented wireless transmission platform designed for mission-critical environments across defense, subsea oil & gas, logistics, telecom, and smart infrastructure. Backed by strong government support and commercial engagement, the company is positioned as a first mover redefining access to the electromagnetic spectrum.
What Differentiates Saltenna
• Deep IP Portfolio — 4 patents granted, 21 pending, 100+ patentable technologies, with ongoing filings
• Government Validation — $7M+ in recent non-dilutive funding from DTRA, USSOCOM, U.S. Air Force, and U.S. Navy
• Commercial Engagement — Active programs with major oil & gas and maritime operators
• Massive Addressable Markets — Multi-trillion-dollar infrastructure sectors spanning defense, energy, logistics, telecom, and smart cities
Event Details:
Date: March 17
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO,
Opus8, Inc.
twong@opus8.com
Soteria Private Investor Briefing - Virtual
Soteria Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
THURSDAY, March 5, 1:00 pm EST
Dear Investors,
Opus8 is hosting an invitation-only virtual private investor briefing featuring Soteria Battery Innovation Group, a company delivering inherently safer lithium-ion batteries through a capital-light, licensing-driven business model.
This private session will provide an opportunity to review the company’s patented materials technology, consortium and licensing strategy, commercial traction with global partners, and upcoming milestones, as well as a discussion of current and future capital formation opportunities for accredited investors.
This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).
Soteria is entering a critical value-creation phase as battery safety shifts from a “feature” to mandatory infrastructure across electric vehicles, aviation, grid storage, and consumer electronics.
Company Overview
Soteria delivers inherently safe battery technology by embedding proprietary, chemistry-agnostic materials inside the battery cell itself, addressing the root cause of lithium-ion battery fires.
The technology reduces battery fire incidents by 90–99% while also lowering battery weight and cost through a significant reduction in copper usage—without requiring changes to existing battery manufacturing processes. Soteria does not manufacture batteries; instead, it operates a scalable licensing and royalty model supported by a global consortium of industrial and strategic partners.
The solution is compatible with virtually all advanced lithium-ion battery chemistries and form factors.
What Differentiates Soteria
Materials-Level Safety Infrastructure — Addresses failure at the source rather than relying on monitoring or post-event mitigation
Chemistry-Agnostic & Manufacturing-Compatible — Integrates into existing battery supply chains without redesign
Capital-Light Licensing Model — Scales through partners rather than manufacturing intensity
Meaningful Cost & Weight Advantages — ~80% reduction in copper usage
Deep Industry Validation — Supported by a global consortium of 130+ active partners
Consortium participants include organizations such as NASA, Mercedes-Benz, Volkswagen, and Lenovo.
Event Details
Date: March 5, 2026
Time: 1:00 - 2:00 PM EST
Location: Online via Zoom
Attendance is strictly limited and curated.
Important Notes
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
To request investor materials in advance, please contact:
Avery North — anorth@opus8.com
If you have any questions, feel free to reach out to me directly. I hope you can join us.
Best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
InventWood Private Investor Briefing - DC
InventWood Private Investor Briefing - DC
by CONNECTpreneur Investor Network
WEDNESDAY, March 4, 5:30 pm EST
Opus8 is hosting a small, invitation-only virtual private investor briefing featuring InventWood, a materials company commercializing SUPERWOOD™, a category-defining biomaterial that delivers the strength of steel with the soul of wood.
This closed-door session will provide direct access to InventWood’s leadership team and a focused discussion of the company’s proprietary materials platform, early commercial traction, manufacturing scale-up, and near-term growth opportunities, including current financing for accredited investors.
InventWood is entering a critical value-creation phase with automated commercial manufacturing live, customer shipments underway, and accelerating demand as steel, aluminum, and concrete face rising costs and structural constraints.
Company Overview
InventWood has commercialized SUPERWOOD™, a breakthrough structural biomaterial that is stronger than steel, significantly lighter, fire resistant, moisture resistant, and carbon sequestering. The company’s proprietary molecular re-engineering process fundamentally transforms wood by eliminating defects and dramatically increasing intrinsic strength and durability.
InventWood is entering the market through premium architectural and exterior building applications while building toward expansion into large structural and infrastructure markets under existing mass-timber codes.
What Differentiates InventWood
• Category-Defining Material — Steel-level strength with wood’s weight, aesthetics, and fire resistance
• Proprietary Platform — Molecular re-engineering that upgrades wood’s intrinsic performance
• Commercialization Underway — Automated SUPERMILL operational with shipments in market
• Defensible IP Position — 140+ issued and pending patents
• Capital-Efficient Scale-Up — Premium early markets fund broader structural expansion
• Large Market Pull — $750B+ addressable markets across construction and infrastructure
Event Details
Date: Thursday, February 26, 2026
Time: 5:30pm EST
Location:
The Capital Grille
200 Park Ave,
New York, NY 10166
Attendance is strictly limited and curated.
Important Notes
This meeting is for DIRECT and ACTIVE private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.
To request investor materials in advance, please contact:
Avery North — anorth@opus8.com
If you have any questions, feel free to reach out to me directly.
I hope you can join us for this private discussion.
Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191
Space Phoenix Systems Private Investor Briefing - Virtual
Space Phoenix Systems Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
WEDNESDAY, March 4, 11:30 am EST
Dear Investors:
Opus8 is hosting a virtual, invitation-only private investor briefing featuring Space Phoenix Systems (SPS), a space logistics company building the infrastructure backbone for microgravity research and in-space manufacturing.
As in-space manufacturing accelerates, SPS lowers the cost and complexity of accessing low Earth orbit (LEO) through streamlined, end-to-end launch and return services—making space-based R&D and production more practical and scalable.
Company Overview
Space Phoenix Systems is developing a cargo-focused, high-cadence, on-demand space logistics fleet in North America. The company provides fully managed launch and return services designed specifically for microgravity research and in-space manufacturing.
By optimizing mission architecture and simplifying access to LEO, SPS enables scientific, government, and industrial customers to conduct space-based research and production more efficiently and cost-effectively.
What Differentiates Space Phoenix Systems
• Strong Market Traction — $300M pipeline, 9 signed LOIs, and a $105M confirmed U.S. government contract
• Cargo-Focused Logistics Model — Dedicated, on-demand space cargo services
• Return-Capable Infrastructure — Economical and reliable return-trip payload delivery
• End-to-End Mission Management — Fully managed solutions that reduce complexity and cost
Event Details:
Date: March 4
Time: 11:30 AM EST
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO,
Opus8, Inc.
twong@opus8.com
InventWood Private Investor Briefing - NYC
InventWood Private Investor Briefing - NYC
by CONNECTpreneur Investor Network
THURSDAY, February 26, 5:30 pm EST
Opus8 is hosting a small, invitation-only virtual private investor briefing featuring InventWood, a materials company commercializing SUPERWOOD™, a category-defining biomaterial that delivers the strength of steel with the soul of wood.
This closed-door session will provide direct access to InventWood’s leadership team and a focused discussion of the company’s proprietary materials platform, early commercial traction, manufacturing scale-up, and near-term growth opportunities, including current financing for accredited investors.
This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).
InventWood is entering a critical value-creation phase with automated commercial manufacturing live, customer shipments underway, and accelerating demand as steel, aluminum, and concrete face rising costs and structural constraints.
Company Overview
InventWood has commercialized SUPERWOOD™, a breakthrough structural biomaterial that is stronger than steel, significantly lighter, fire resistant, moisture resistant, and carbon sequestering. The company’s proprietary molecular re-engineering process fundamentally transforms wood by eliminating defects and dramatically increasing intrinsic strength and durability.
InventWood is entering the market through premium architectural and exterior building applications while building toward expansion into large structural and infrastructure markets under existing mass-timber codes.
What Differentiates InventWood
• Category-Defining Material — Steel-level strength with wood’s weight, aesthetics, and fire resistance
• Proprietary Platform — Molecular re-engineering that upgrades wood’s intrinsic performance
• Commercialization Underway — Automated SUPERMILL operational with shipments in market
• Defensible IP Position — 140+ issued and pending patents
• Capital-Efficient Scale-Up — Premium early markets fund broader structural expansion
• Large Market Pull — $750B+ addressable markets across construction and infrastructure
Event Details
Date: Thursday, February 26, 2026
Time: 5:30pm EST
Location: The Capital Grille
200 Park Ave,
New York, NY 10166
Attendance is strictly limited and curated.
Important Notes
This meeting is for DIRECT and ACTIVE private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.
To request investor materials in advance, please contact:
Avery North — anorth@opus8.com
If you have any questions, feel free to reach out to me directly.
I hope you can join us for this private discussion.
Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191
Alphyn Biologics Private Investor Briefing - Virtual
Alphyn Biologics Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
TUESDAY, February 24, 11am EST
Opus8 is hosting a small, invitation-only investor meeting featuring Alphyn Biologics, a late-clinical dermatology company entering Series B formation.
This closed-door session will provide direct access to the Alphyn management team and an opportunity to review recent clinical progress and upcoming milestones.
Company Overview
Alphyn Biologics is a late-clinical dermatology company developing patented, plant-derived topical therapeutics, led by a Phase 2a–completed asset in Atopic Dermatitis with additional pipeline programs including Molluscum Contagiosum Virus (MCV).
What Differentiates Alphyn
Huge Market - Multi-target topical mechanism addressing multiple disease drivers
Excellent Traction - Recently closed on $15 million Series A
Strong safety and tolerability profile to date
Patent protection in the U.S. and Europe extending to 2043
Secured, regulatory-compliant raw material supply
Event Details
Date: Tuesday, February 24, 2026
Time: 11 AM EST
Location: Online via Zoom
Attendance is limited and curated.
Important Notes
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
To request investor materials, contact:
Avery North — anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
InventWood Private Investor Briefing - Virtual
InventWood Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
THURSDAY, February 19, 11:30 am EST
Opus8 is hosting a small, invitation-only virtual private investor briefing featuring InventWood, a materials company commercializing SUPERWOOD™, a category-defining biomaterial that delivers the strength of steel with the soul of wood.
This closed-door session will provide direct access to InventWood’s leadership team and a focused discussion of the company’s proprietary materials platform, early commercial traction, manufacturing scale-up, and near-term growth opportunities, including current financing for accredited investors.
This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).
InventWood is entering a critical value-creation phase with automated commercial manufacturing live, customer shipments underway, and accelerating demand as steel, aluminum, and concrete face rising costs and structural constraints.
Company Overview
InventWood has commercialized SUPERWOOD™, a breakthrough structural biomaterial that is stronger than steel, significantly lighter, fire resistant, moisture resistant, and carbon sequestering. The company’s proprietary molecular re-engineering process fundamentally transforms wood by eliminating defects and dramatically increasing intrinsic strength and durability.
InventWood is entering the market through premium architectural and exterior building applications while building toward expansion into large structural and infrastructure markets under existing mass-timber codes.
What Differentiates InventWood
• Category-Defining Material — Steel-level strength with wood’s weight, aesthetics, and fire resistance
• Proprietary Platform — Molecular re-engineering that upgrades wood’s intrinsic performance
• Commercialization Underway — Automated SUPERMILL operational with shipments in market
• Defensible IP Position — 140+ issued and pending patents
• Capital-Efficient Scale-Up — Premium early markets fund broader structural expansion
• Large Market Pull — $750B+ addressable markets across construction and infrastructure
Event Details
Date: Thursday, February 19, 2026
Time: 11:30am EST
Location: Online via Zoom
Attendance is strictly limited and curated.
Important Notes
This meeting is for DIRECT and ACTIVE private investors only. All attendees must pre-register via this Eventbrite page and complete the investor qualification criteria. All RSVPs are subject to review and approval.
To request investor materials in advance, please contact:
Avery North — anorth@opus8.com
If you have any questions, feel free to reach out to me directly.
I hope you can join us for this private discussion.
Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191
Maxwell Biosciences Private Investor Meeting - Virtual
Maxwell Biosciences Private Investor Meeting - Virtual
by CONNECTpreneur Investor Network
TUESDAY, February 17, 11:30am EST
Dear Investors:
Opus8 is hosting a virtual, invitation-only virtual private investor briefing featuring Maxwell Biosciences, a clinical-stage biotechnology company advancing a first-in-class Synthetic Immune System™ platform designed to transform the treatment of infectious diseases.
This closed-door session will provide direct access to Maxwell’s leadership team and an opportunity to review the company’s Claromer™ technology, extensive scientific and government validation, lead clinical strategy, and upcoming FDA milestones, as well as a discussion of current and future financing opportunities for accredited investors.
Maxwell is entering a critical value-creation phase, supported by strong Pre-IND FDA feedback and an anticipated IND submission in 2026, positioning the company for meaningful clinical and strategic inflection points. Maxwell is uniquely positioned at the intersection of antimicrobial resistance, biodefense preparedness, and next-generation anti-infectives—areas now prioritized by governments, regulators, and strategic pharma partners worldwide.
Company Overview
Maxwell Biosciences has developed an AI-driven drug discovery platform that creates synthetic small molecules designed to mimic LL-37, the human immune system’s primary antimicrobial peptide. Unlike traditional antibiotics, Maxwell’s Claromers™ are broadly effective against nearly all tested bacterial and fungal pathogens—including drug-resistant strains and biofilms—without inducing resistance.
The platform is supported by over $65 million in non-dilutive government grants and investor financing, more than 250 peer-reviewed scientific publications, and seven U.S. military Collaborative Research and Development Agreements. Maxwell’s lead clinical program is targeting Chronic Rhinosinusitis (CRS), with Phase 1 clinical trials anticipated in 2026.
What Differentiates Maxwell Biosciences
• First-in-Class Synthetic Immune System™ — Small molecules designed to replicate natural human immunity rather than target single pathogens
• Broad-Spectrum, Resistance-Free Activity — Demonstrated efficacy against hundreds of bacterial and fungal pathogens, including drug-resistant strains and biofilms
• AI-Driven Claromer™ Platform — Rapid creation of a scalable library of drug candidates across multiple infectious disease indications
• Strong Government & Military Validation — DARPA-seeded platform supported by $65M+ in non-dilutive funding and active U.S. defense and public health collaborations
• Compelling Regulatory & IP Profile — Encouraging FDA Pre-IND feedback, robust composition-of-matter patents, and high likelihood of Qualified Infectious Disease Product (QIDP) designation with extended market exclusivity
• Massive Market Opportunity — Positioned to address a global infectious disease market projected to exceed $190B, with platform-level expansion across pharma, government stockpiling, and strategic partnerships
Event Details
Date: Tuesday, February 17, 2026
Time: 11:30am - 12:30pm EST
Location: Online via Zoom
Attendance is strictly limited and curated.
Important Notes
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com
If you have any questions, feel free to reach out to me directly. I hope you can join us for this important discussion.
Best,
Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191
Soteria Private Investor Briefing - Palo Alto
Soteria Private Investor Briefing - Palo Alto
by CONNECTpreneur Investor Network
THURSDAY, February 12, 5:30pm PST
Opus8 is hosting a small, invitation-only private investor briefing featuring Soteria Battery Innovation Group, a company delivering inherently safer lithium-ion batteries through a capital-light, licensing-driven business model.
This closed-door session will provide direct access to Soteria’s leadership team and an opportunity to review the company’s patented materials technology, consortium and licensing strategy, commercial traction with global partners, and upcoming milestones, as well as a discussion of current and future capital formation opportunities for accredited investors.
Soteria is entering a critical value-creation phase as battery safety shifts from a “feature” to mandatory infrastructureacross electric vehicles, aviation, grid storage, and consumer electronics.
Company Overview
Soteria delivers inherently safe battery technology by embedding proprietary, chemistry-agnostic materials inside the battery cell itself, addressing the root cause of lithium-ion battery fires.
The technology reduces battery fire incidents by 90–99% while also lowering battery weight and cost through a significant reduction in copper usage—without requiring changes to existing battery manufacturing processes. Soteria does not manufacture batteries; instead, it operates a scalable licensing and royalty model supported by a global consortium of industrial and strategic partners.
The solution is compatible with virtually all advanced lithium-ion battery chemistries and form factors.
What Differentiates Soteria
Materials-Level Safety Infrastructure — Addresses failure at the source rather than relying on monitoring or post-event mitigation
Chemistry-Agnostic & Manufacturing-Compatible — Integrates into existing battery supply chains without redesign
Capital-Light Licensing Model — Scales through partners rather than manufacturing intensity
Meaningful Cost & Weight Advantages — ~80% reduction in copper usage
Deep Industry Validation — Supported by a global consortium of 130+ active partners
Consortium participants include organizations such as NASA, Mercedes-Benz, Volkswagen, and Lenovo.
Event Details
Date: February 12, 2026
Time: 5:30 - 7:30 PM PST
Location: Fleming’s Prime Steakhouse & Wine Bar
180 El Camino Real G-2,
Palo Alto, CA 94304
Attendance is strictly limited and curated.
Important Notes
This meeting is intended for direct, active private investors and strategic capital only
All attendees must pre-register via this Eventbrite page and complete investor qualification criteria
All RSVPs are subject to review and approval
To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com
If you have any questions, feel free to reach out to me directly. I hope you can join us in Palo Alto.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
M 703 932 9191
Actuated Medical Private Investor Briefing - Virtual
Actuated Medical Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
WEDNESDAY, February 11, 11 am EST
Opus8 is hosting an invitation-only virtual private investor briefing featuring Actuated Medical, a medical device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment.
You will be able to meet the Actuated Medical leadership team and will be given an opportunity to review the company’s neuro platform, clinical direction, and upcoming milestones, as well as its broader strategic roadmap.
Company Overview
Actuated Medical is a med device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment. The company also maintains a portfolio of FDA-cleared technologies, providing strategic and financial optionality as it advances its core neuro program.
What Differentiates Actuated Medical
Large Neurological Opportunity — Platform technology addressing significant unmet needs in neuro procedures
Proprietary Engineering — Differentiated design enabling precision access and delivery
Clinical Momentum — Active engagement with leading clinicians and academic medical centers
Strategic Optionality — FDA-cleared assets alongside a focused neuro platform
Experienced Leadership — Proven device development and commercialization expertise
Event Details
Date: Wednesday, February 11, 2026
Time: 11 AM – 12 PM EST
Location: Online via Zoom
Attendance is limited and curated.
Important Notes
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
To request investor materials, contact:
Avery North — anorth@opus8.com
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
Big Idea CONNECTpreneur Baltimore Forum - Feb 5th IN PERSON
Come join us in Baltimore, MD for a CONNECTpreneur Forum Event like you've never seen before! This event is set to be a smaller and more exclusive gathering, tailor-made for premium networking and connecting entrepreneurs with seasoned investors. With CONNECTpreneur's track record of fostering valuable connections and driving investment opportunities, attendees can expect an unparalleled platform to fuel their business growth.
Tickets will go FAST, as we only have a VERY limited number available!
CONNECTpreneur is a bi-monthly networking mashup, which has been attended by over 40,000 business leaders since 2011.
Space is very limited at this venue, and we expect another Sold Out crowd, so there will be no on-site registration.
All attendees must be pre-registered.
Continental breakfast and unlimited coffee will be provided.
Program Highlights:
- We are capping attendance at 200 business leaders, including 75+ angels and private investors, family offices, etc.
- Investor and VIP Speakers who are deeply rooted in our community, sharing their insider knowledge and showcasing the innovation thriving in our region.
- Heavy networking before, during, and after the event
Company Showcase:
We will have a Rocket Pitch session with emerging tech companies: a dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.
Angiex Private Investor Briefing - Virtual
Angiex Private Investor Briefing - Virtual
by CONNECTpreneur Investor Network
TUESDAY, February 3, 11:30am EST
Opus8 is hosting a small, invitation-only private investor briefing featuring Angiex, a clinical-stage oncology company advancing a first-in-class platform of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) for solid tumors.
This closed-door session will provide direct access to Angiex’s leadership team and an opportunity to review the company’s lead Phase 1 clinical program, emerging clinical signals, platform differentiation, and upcoming milestones, as well as a discussion of current financing opportunities for accredited investors.
Angiex is entering a critical value-creation phase, with early clinical data beginning to inform downstream strategic and capital formation decisions.
Company Overview
Angiex is developing a new class of antibody-drug conjugates designed to deliver therapeutic payloads directly to the nucleus of tumor cells and tumor-associated vasculature. The company’s lead asset, AGX101, targets TM4SF1, a protein highly expressed in tumor blood vessels and tumor cells, with limited expression in normal adult tissues.
AGX101 is currently in Phase 1 clinical trials in patients with advanced solid tumors and has demonstrated an exceptional safety profile alongside early signs of clinical activity, including stable disease and tumor shrinkage at higher dose levels.
What Differentiates Angiex
• First-in-Class Nuclear-Delivered ADC Platform — Designed to bypass traditional ADC resistance mechanisms through direct nuclear payload delivery
• Validated Tumor Target (TM4SF1) — Enables dual targeting of tumor vasculature and tumor cells
• Three Complementary Mechanisms of Action — Vascular deprivation, immune activation, and direct tumor cell killing
• Outstanding Safety Profile — No observed adverse effects in primate studies at the highest dose tested
• Early Clinical Validation — On-target pharmacodynamics and emerging tumor response in Phase 1
Event Details
Date: Tuesday, February 3, 2026
Time: 11:30 – 12:30 PM EST
Location: Online via Zoom
Attendance is strictly limited and curated.
Important Notes
This meeting is intended for direct and active private investors only.
All attendees must pre-register via this Eventbrite page and complete investor qualification criteria.
All RSVPs are subject to review and approval.
To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com
If you have any questions, feel free to reach out to me directly. I hope you can join us Monday evening.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com
M 703 932 9191